As of November 5, 2026. Every statement about MEDVi below links to its source.
The short answer: MEDVi is a real company. It sells compounded GLP-1 weight-loss programs online, its site says OpenLoop Health clinicians make the prescribing decision, and it lists three partner pharmacies without saying which one fills your order. Its public record is a reason to check before you pay: an FDA warning letter in February 2026, two pending privacy class actions, an F rating from the Better Business Bureau, press reports of ads run under apparently fabricated doctor personas, and an advertised price that changes with promotions while the price for your dose is not shown before intake.
This is a dated record built from MEDVi's own pages, FDA's records, federal court dockets, BBB, and named press. Where something is an allegation, we say so. If MEDVi changes its service or its record changes, we will update this page.
Who runs MEDVi
MEDVi's Terms and Conditions name the company as MEDVi, LLC, which they describe as "a Delaware corporation," at 131 Continental Dr, Ste 305, Newark, Delaware.
MEDVi's site attributes prescribing to other companies. Its homepage says: "OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients." The footer adds that medical treatment is provided by "CareGLP Affiliated P.C.s," and OpenLoop Health. The site names no individual prescriber. Drug Discovery & Development reported that MEDVi removed the two physicians it had listed from its website on April 10, 2026, and that CareValidate and OpenLoop handle the doctors, pharmacies, shipping, and compliance.
OpenLoop Health, the clinician network MEDVi's site names, reported a breach affecting 716,000 people to HHS (submitted March 17, 2026), as the HHS Office for Civil Rights breach portal lists it (search OpenLoop Health). SecurityAffairs reported the same 716,000 figure for a January 2026 breach at OpenLoop. The named plaintiff in a February 19, 2026 class action against OpenLoop over the January 2026 breach alleges she used MEDVi in 2025 (S.D. Iowa 4:26-cv-00083); MEDVi is not a defendant in that suit. The plaintiff's claims are allegations.
MEDVi's homepage footer and Terms list three partner pharmacies: Triad Rx in Daphne, Alabama; RedRock Pharmacy in St. George, Utah; and Beaker Pharmacy & Compounding in McKinney, Texas. They do not say which one will fill your order. The Terms say "you may be entering into a relationship with a pharmacy." In an April 2025 reply on BBB to a customer who had asked for a specific pharmacy, MEDVi wrote, "Unfortunately, our system does not allow us to select a preferred pharmacy, but the agents who received your request made every effort to explore possible options on your behalf."
How big is it? The New York Times reported on April 2, 2026 that MEDVi had $401 million in 2025 sales and 250,000 customers, run by two employees plus contractors, and that its support chatbot had made up drug prices, which the company then honored. We did not open the Times article; those figures are as PYMNTS and Techdirt quoted it, and the Times later edited the piece and added an editor's note. MEDVi's GLP-1 page now says "Join 500,000+ MEDVi patients."
What MEDVi charges, and what it does not show
Start with what you cannot see. Before intake, MEDVi's GLP-1 page shows no price for a specific dose, and its pages do not say which pharmacy will fill your order. Its Terms say "the final charge to your credit card may fluctuate contingent upon the prescribed medication and the chosen pharmacy for order fulfillment." So there is no way to see, before you pay, what your dose costs or which pharmacy fills it.
What the GLP-1 page does show is a program price. As of November 5, 2026, it opens with "FALL Sale! Only $99" and says the semaglutide program "starts at $99 for your first month." The same page says: "Refills are locked in at $199." GLP-1 tablets are "Starting at $249." Branded Wegovy and Zepbound are listed as "$99 Membership + Medication Cost," on a page that also says "No membership or hidden fees!" No compounded tirzepatide is listed.
The price has moved before. Archived copies of medvi.org from April 6, 2025, July 4, 2025, and December 8, 2025 advertised GLP-1 injections "Starting at $179" and a program that "starts at $179 for your first month," with "Refills are locked in at $299." Ozempic was listed at "$1,999/mo." A second domain, medvi.io, the one FDA's letter concerns, advertised "Start for just $179" with "Save $120" promotions from September 2025 through January 2026.
"Monthly" also needs a footnote. In its replies to complaints on BBB, MEDVi describes "a subscription plan that operates on a recurring 28-day billing cycle." A 28-day cycle bills 13 times a year, not 12.
MEDVi's other replies on BBB explain how the cycle runs. One, dated June 17, 2026, says "recurring charges may process regardless of whether a refill intake has been completed." Another, dated May 14, 2026, says "refund requests during an active billing cycle must be submitted at least 72 hours prior to the billing date to qualify for refund," and that if a customer's doctor has advised stopping treatment, "we would need documentation or a note from your PCP in order to further review refund eligibility."
MEDVi's cancellation and refund policy gives a full refund within 72 hours of the subscription start if no services were received, or if a provider disqualifies you; on plans charged two or more months at a time, it refunds the months in which no medication shipped. On monthly plans, it says in capital letters that you will not be refunded for the month in which you cancel or for any earlier month. A cancellation must reach MEDVi at least 72 hours before the next billing date.
The guarantee language has changed too. On February 17, 2026, a feature strip on MEDVi's refund policy page read "MEDVi money back guarantee"; by March 5 the strip read "MEDVi guarantee" and the policy added "There is no guarantee of results or effectiveness due to your participation in the Subscription Services." The current policy keeps a version of that sentence. As of November 5, 2026, a GLP-1 page on quad.medvi.org says "we guarantee you'll lose weight or your money back." MEDVi's medical consent says "There are no refunds or exchanges" and has the patient certify: "I will not dispute the payments with my credit card company."
What FDA said
On February 20, 2026, FDA's Center for Drug Evaluation and Research sent MEDVi, LLC a warning letter about its website medvi.io, which FDA had reviewed in December 2025. The letter came from FDA's Office of Compounding Quality and Compliance.
The letter says the product labels pictured on the site suggested "MEDVi is the compounder of those drugs when in fact it is not." It quoted two claims from the site: "Same active ingredient as Wegovy® and Ozempic®." and "Same active ingredient as Mounjaro® and Zepbound®." Of those, the letter says: "Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." FDA cited misbranding under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act and warned that failing to address the violations "may result in legal action without further notice, including, without limitation, seizure and injunction."
A warning letter is FDA's allegation and a request for a response, not a court finding. As of November 5, 2026, FDA's warning-letter index lists this one letter to MEDVi and no close-out letter.
MEDVi disputes whom the letter concerned. In a statement Futurism reported on April 9, 2026, MEDVi said the letter "was directed at an affiliate marketing agency" and that it had never received a letter from the FDA. FDA addressed the letter to "MEDVi, LLC dba MEDVi." Archived copies of medvi.io from August 7, 2025 through December 11, 2025 carry an "Affiliate Relationship Disclosure," and Futurism wrote that medvi.io had no affiliate disclaimers when it first reported on MEDVi in May 2025. Futurism also reported that in December 2025, when FDA reviewed medvi.io, the homepage of medvi.org, which MEDVi calls its primary domain, showed the same MEDVi-branded bottles.
Today's GLP-1 page says in its fine print that the compounded medications "are not FDA-approved or evaluated for safety, efficacy, or quality." The page body above it uses the phrases "Trusted by experts" and "doctor-approved."
Those two phrases came up before. On September 22, 2025, the National Consumers League and 12 other organizations petitioned the FTC about compounded GLP-1 advertising. The petition names MEDVi and cites a MEDVi Instagram ad saying "trusted by experts" and "doctor-approved" with no substantiating claims from doctors. A petition is a request, not a finding, and we found no FTC or state attorney general action against MEDVi.
In court
Two class actions filed in federal court in the Central District of California in April 2026 concern privacy: E.P., J.S., M.A. v. Medvi LLC (2:26-cv-03796, filed April 9) and J.F. v. Medvi LLC (2:26-cv-04247, filed April 21). They bring claims under the federal Wiretap Act, the California Invasion of Privacy Act, and California's Confidentiality of Medical Information Act. The plaintiffs allege that MEDVi told users their information is "never shared" while sending intake-page addresses that carried users' email addresses "in plaintext" to Google (complaint). These are allegations. MEDVi has moved to compel arbitration, and the hearing is set for November 19, 2026.
A third suit, James v. Medvi LLC (8:26-cv-00641, filed March 20, 2026), alleged spam email from affiliates under California's anti-spam law. The plaintiff voluntarily dismissed it on July 17, 2026. Articles from early April that call it pending were written before the dismissal.
In all, CourtListener's RECAP archive lists six federal suits naming MEDVi, LLC as a defendant since May 2025: the two privacy class actions, the anti-spam suit above, and three text-message suits under the federal Telephone Consumer Protection Act (1:25-cv-22185, 2:25-cv-11282, and 2:26-cv-04323). Three of the six have been dismissed. Each is an allegation, not a finding. We searched federal dockets only, not state courts or private arbitration.
How MEDVi advertises
MEDVi's GLP-1 page shows the line "Proud To Be Featured And Advertised In" above the logos of Bloomberg, Forbes, Healthline, WebMD, Fortune, Fast Company, and The New York Times. In May 2025, Futurism looked and found no sign of MEDVi coverage in the New York Times, Bloomberg, or the other outlets, apart from a Forbes Health "Best Weight Loss Injections Of 2025" roundup that listed MEDVi under an independence disclaimer. The New York Times later reported that MEDVi had "merely advertised there," as Techdirt quoted it.
In April 2026, Drug Discovery & Development counted more than 5,000 active Meta ads for "medvi," many under apparently fabricated doctor personas. MEDVi's site fine print read at the time: "Individuals appearing in advertisements may be actors or AI portraying doctors and are not licensed medical professionals." (It now says "actors or models.") Business Insider reported, as DD&D relayed it, that "maybe 30%" of MEDVi's advertising ran through affiliates, and that the active ads fell to about 2,800 after Business Insider asked about them. MEDVi's statement to Futurism said it had only recently become aware of those ads.
The testimonials have a record too. In May 2025, Futurism reported that before-and-after photos of MEDVi "patients" were real images from elsewhere with AI-altered faces, one of them traced to a 2018 Daily Mail story, and that a doctor listed on the site said he had nothing to do with the company. In April 2026, Techdirt reported, quoting a Futurism follow-up, that an archived copy of medvi.org from March 2026 showed the same patient names with different people, some with clear signs of AI generation.
What customers report
The Better Business Bureau rates MEDVi F and lists it as not accredited. BBB calls a rating its opinion of how a business is likely to interact with its customers. It lists 789 complaints in the last three years, 657 of them in the last 12 months, and gives "Failure to respond to 147 complaint(s)" as a reason for the rating. Customer reviews there average 1.82 of 5 across 639 reviews. The 2026 complaints return to the same themes: charges after a cancellation or pause request, renewal charges with no shipment until a refill form is done, repeated charge attempts, refunds refused for the current cycle, and bundles shipped in part. BBB asks readers to weigh a company's size and volume of transactions, and a large company draws more complaints.
Trustpilot tells a different story. An archived copy of MEDVi's Trustpilot page from March 13, 2026 shows a TrustScore of 4.5 across 10,676 reviews: 8,473 five-star reviews (79%) and 1,049 one-star reviews (9.8%). Reviews there are labeled "Invited," meaning the company asked the customer to review, and the page says MEDVi "Replied to 99% of negative reviews." The live page blocked our reader, so we could not confirm today's figures.
MEDVi and Temi, side by side
| MEDVi (as of November 5, 2026) | Temi | |
|---|---|---|
| Price for your dose before you pay | Not shown before intake (GLP-1 page) | Shown for every partner pharmacy |
| Pharmacy | One of three listed partners; not named for your order (Terms) | You choose it, by name and price |
| Final charge | Its Terms say it "may fluctuate" with the medication and pharmacy (Terms) | Shown before you pay: the pharmacy's price for your dose and the $39 prescription service |
| Advertised price | $99 first month, refills "locked in at $199" (GLP-1 page) | No program price; each partner pharmacy's price for your dose |
| When you are charged | At enrollment, then every 28 days (BBB replies) | Card held at checkout; charged when the physician decides |
| Renewal | Recurring 28-day billing cycle (BBB replies) | Only when you place a new order |
| Who prescribes | "OpenLoop Health clinicians" (homepage); no individual named | Kevin Brandstetter, M.D., or another physician licensed in your state |
| Compounded tirzepatide | Not listed on its GLP-1 page | Offered, if prescribed |
Five checks before you pay any GLP-1 provider
- Can you see the price for your dose before intake? A first-month price is not the price of the dose you will be on in month four.
- Which pharmacy fills it? A provider should name the pharmacy before you pay, so you know who compounds your medication.
- When are you charged, and how does it renew? Read the billing cycle in days, not "monthly," and read the cancellation terms before you enter a card.
- Who prescribes? Look for a named physician and the medical group behind the program.
- What has FDA said? Search FDA's warning-letter index for the company's name, and be wary of any claim that a compounded drug is the same as a brand-name one. Compounded semaglutide and tirzepatide are not FDA-approved.
Where Temi fits
Temi is a prescription service, not a pharmacy. You answer a health questionnaire and pick the partner pharmacy yourself. Each partner pharmacy's name and price for your dose show before you pay; compare them for compounded semaglutide and compounded tirzepatide. If prescribed, you pay that price plus Temi's $39 prescription service, or $0 with Temi Care at $449 a year. Your card is held at checkout and charged when the physician decides, and an order never renews by itself.
A licensed physician decides whether to prescribe. Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products; a licensed 503A compounding pharmacy prepares each one for a single prescription. Temi serves patients located in Arizona, California, Colorado, Delaware, Florida, Michigan, Missouri, New York, North Carolina, Ohio, Pennsylvania, Texas, and Wisconsin.
See Temi and MEDVi compared on one page.
This record reflects MEDVi's pages, FDA's records, the court dockets, HHS's breach portal, BBB, and the press reports linked above, as read on November 5, 2026. Allegations in lawsuits and FDA letters are not findings of wrongdoing. If MEDVi responds or the record changes, we will update this article.
Frequently asked questions
Is MEDVi a real company?
Did the FDA send MEDVi a warning letter?
Yes. FDA sent MEDVi, LLC a warning letter dated February 20, 2026, about claims on medvi.io. The letter says its labels suggested MEDVi compounded the drugs and that its "same active ingredient" claims implied FDA approval. As of November 5, 2026, FDA's index shows no close-out letter. MEDVi has said the letter was directed at an affiliate. A warning letter is not a court finding.
How much does MEDVi cost?
Its GLP-1 page shows no price for your dose before intake, and its Terms say the final charge "may fluctuate" with the medication and the pharmacy. As of November 5, 2026, the page advertises $99 for the first month and refills "locked in at $199." Earlier copies of the site advertised $179 and $299. Its replies on BBB describe a recurring 28-day billing cycle, which bills 13 times a year.
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription, and a licensed physician decides whether either is right for you.
